Wave Life Sciences rises on Q4 revenue beat, smaller-than-expected loss

Wave Life Sciences

06/03/2024 15:17

** Shares of drug developer Wave Life Sciences  WVE.O  rise
21.9% to $5.84 
    ** Reports Q4 revenue of $29.06 mln, handily beating
analysts' average estimate of $19.86 mln - LSEG data  
    ** Posts adj. loss of 15 cents per share vs analysts'
estimates of loss of 23 cents
     ** Says current cash and cash equivalents will be
sufficient to fund operations into the fourth quarter of 2025
    ** Cash and cash equivalents were $200.4 mln, as of Dec.31  
 
    

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))